Results 71 to 80 of about 12,232 (185)

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis

Scientific Reports
Recent case reports linked use of the lipid-lowering class of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to severe hypersensitivity reactions.
Foteini Dermiki-Gkana, Christopher A. Gravel, Christos Kontogiorgis, Antonios Douros   +3 more
doaj   +1 more source

Cholesterol and stroke: role of PCSK9 inhibitors

Neurología (English Edition), 2019
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the modulation of plasma levels of low density lipoprotein cholesterol (LDLC). PCSK9 binds to the LDL receptor (LDLR), disrupts its endocytic recycling itinerary and directs it to lysosomal degradation.
L. Castilla-Guerra, M.C. Fernández-Moreno, M.A. Rico-Corral   +2 more
openaire   +4 more sources

A Cryoprotectant‐Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals

Advanced Materials, Volume 38, Issue 33, 12 June 2026.
A cryoprotectant‐compatible nanoporous platform enables ambient‐stable and scalable delivery of gene editing therapeutics. By combining hierarchical pore architecture with optimized lyophilization chemistry, the system preserves Cas9‐RNP activity post‐freeze‐drying.
Sian Lee, Seongchan Kim, Jooyeun Chong, Min‐gyeong Kim, Kayeong Lim, Nan‐Ee Lee, Jahyun Koo, Jiheong Kang, Hyojin Lee   +8 more
wiley   +1 more source

Fibrates Inhibit PLTP‐induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang, Yaning Li, Jianxun Cai, Lisi Luo, Pengfei Yang, Yutong Chen, Jiancong Zhou, Yan Zeng, Jiaping Yu, Weiyu Zhang, Wenzheng Pang, Yufang Li, Chunhua Wen, Jian Li, Linjuan Zeng   +14 more
wiley   +1 more source

APOE and Cerebral Microbleeds: Insights Into Causal Proteins and Therapeutic Targets

Brain and Behavior, Volume 16, Issue 6, June 2026.
This study identifies APOE as a key causal protein for cerebral microbleeds (CMBs). By integrating Mendelian randomization (MR) and colocalization analysis of the plasma proteome from UKB‐PPP and deCODE datasets, we provide genetic evidence that circulating APOE levels are causally linked to CMB susceptibility. Furthermore, protein–protein interaction (
Lei Yang, Jian‐Lan Zhao, Jie Song, Lin‐Hui Chen, Chun Yu, Qiang Yuan, Gang Wu, Jin Hu, Mei‐Hua Wang   +8 more
wiley   +1 more source

Homeobox B13 activates the hypoxia‐inducible factor 1 pathway through histone lactylation thereby reprogramming lipid metabolism and promoting sorafenib resistance in hepatocellular carcinoma

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Lactylation‐mediated metabolism reprogramming in HCC sorafenib resistance. In sorafenib‐resistant hepatocellular carcinoma (HCC) cells, lactate accumulation drives histone H3 lysine 18 lactylation (H3K18la). This modification is specifically enriched in the promoter region of homeobox B13 (HOXB13), activating HOXB13 transcription and upregulating its ...
Qingqing Xie, Fangxia Teng, Ting Ding, Huaizhe Zhang, Jian Huang, Shu Zhang   +5 more
wiley   +1 more source

Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 6, June 2026.
ABSTRACT Background High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its ...
Emad Uddin Sajid, Muhammad Hasnain Azeem, Alishba Fatima, Syeda Masooma Jafri, Danish Hassan, Taha Ibrahim, Kashish Zehra Manjee, Syed Rayyan Ahmed, Tooba Ali, Rida Shakeel, Muhammad Usman, Raghabendra Kumar Mahato, Danish Bawa   +12 more
wiley   +1 more source

Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

Diseases
The primary objective of this study was to conduct a cost–utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease.
José Seijas-Amigo, Maria José Mauriz-Montero, Pedro Suarez-Artime, Mónica Gayoso-Rey, Francisco Reyes-Santías, Ana Estany-Gestal, Antonia Casas-Martínez, Lara González-Freire, Ana Rodriguez-Vazquez, Natalia Pérez-Rodriguez, Laura Villaverde-Piñeiro, Concepción Castro-Rubinos, Esther Espino-Paisán, Octavio Cordova-Arevalo, Diego Rodriguez-Penas, Begoña Cardeso-Paredes, Marta Ribeiro-Ferreiro, Moisés Rodríguez-Mañero, Alberto Cordero, José R. González-Juanatey, MEMOGAL Investigators   +20 more
doaj   +1 more source

Sensing and Communicating β‐Cell Stress in the Context of T1D Etiology: New Opportunities for Therapeutic Impact

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
Type 1 diabetes (T1D) results from the immune‐mediated destruction of insulin‐producing pancreatic β‐cells. Recent human studies show that early β‐cell stress maladaptations precede overt immune cell infiltration. DOC2B, a vesicle secretion regulatory protein that supports β‐cell functionality and resilience against stress, declines early in T1D ...
Diana Esparza, Chathurani S. Jayasena, Tijana Jovanovic‐Talisman, Debbie C. Thurmond   +3 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source